BLCO
NYSE Bausch + Lomb Corporation$16.84 ↑ +0.23 (+1.38%) Trading Up from the previous close of $16.61, $0.10 below the day’s high of $16.94
- YTD change
- -1.41%
- vs 20-day SMA
- -0.06%
- vs 200-day SMA
- +1.32%
Price ranges
Price & Performance
-0.15 (-0.89%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 23.3% away from all-time highs of $21.95
- BLCO is down 1% since the beginning of the year
- BLCO is up 7% over the past 12 months
- BLCO is up 0% over the past 1 month
- 7% of all BLCO investors are betting against BLCO
- Number of investors short BLCO has gone down 13% versus last month
BLCO reads very good: price sits above one of the two key moving averages, short interest is falling month over month, the 12-month move is +5.5%.
- Previous minute
- +$0.00
- Last hour
- +$0.11
- Last 5 days
- +4.79%
- vs 8-day SMA
- +1.96%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
